[A case of complicated perioperative management of radical nephrectomy in a patient with a drug-eluting stent].
Drug-eluting stents (DES) are commonly used for coronary artery disease and patients with DES require antiplatelet therapy because of the risk of late stent thrombosis. Accordingly problems can occur in the perioperative period due to late thrombosis of a stent after discontinuation of antiplatelet therapy before surgery. A 64-year-old man was diagnosed as having a right renal tumor (T1aN0M0) and his performance status was 4. Three years earlier, a DES had been placed in a coronary artery and he was taking aspirin plus ticlopidine. These drugs were stopped at 7 days before surgery and we started heparin (15,000 U/day). Heparin was continued during and after radical nephrectomy. Although operative blood loss was only 178 ml, the amount of bleeding within 5 hours after surgery was 1,620 ml. The wound was re-opened, but there was no obvious bleeding source, so oozing from the muscle was controlled. His blood pressure dropped and cardiac arrest occurred at 22 hours after re-operation, but he was resuscitated with blood transfusion and the bleeding stopped after the dose of heparin was reduced. Three days after the operation, antiplatelet therapy was re-started and heparin was ceased at 10 days after surgery. The blood clot in the right retroperitoneal space formed an abscess at 28 days after radical nephrectomy. After drainage, the retroperitoneal space was washed twice a day for about 40 days. The wound healed, and he currently has no evidence of recurrence or metastasis and has no cardiac sequelae.
The Division of Urology, Department of Organ-oriented Medicine, Faculty of Medicine, University of the Ryukyus, Japan.
Eiri
E
Matsumura
Hiroyuki
H
Yonou
Shinsuke
S
Tasaki
Tomotsune
T
Toyosato
Satoshi
S
Ashimine
Noriko
N
Machida
Masato
M
Goya
Yoshinori
Y
Oshiro
Seiichi
S
Saito
D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects; D001803:Blood Transfusion; D054855:Drug-Eluting Stents; D006470:Hemorrhage / Q000139:chemically induced; D006493:Heparin / Q000008:administration & dosage; D006801:Humans; D007680:Kidney Neoplasms / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009392:Nephrectomy; D019990:Perioperative Care / Q000379:methods*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D012187:Retroperitoneal Space
D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D006493:Heparin